All Video
-
VIDEOIgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptoms
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptoms